# Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

> **NCT03381053** · — · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 3000 (estimated)

## Conditions studied

- Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST

## Interventions

- **DRUG:** Imatinib 400mg

## Key facts

- **NCT ID:** NCT03381053
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2020-07-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2017-12-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381053, "Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03381053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*